Most Recent
Bristol-Myers Squibb unit Celgene and two generic drug makers have withdrawn an application for ACCC approval of a patent settlement that would have allowed for an early launch of a generic version of blockbuster cancer drug Revlimid.
German pharmaceutical giant Bayer, which is facing a legal bid by generic drug maker Sandoz to invalidate patents covering blood clot drug Xarelto, is seeking to amend one of the patents in dispute.
An Australian non-practicing entity alleging Apple's Touch ID and Face ID technology infringes its patents has accused the Silicon Valley company of refusing to comply with court orders to hand over documents.
The Full Federal Court has rejected German drug maker Boehringer Ingelheim's appeal of ruling that shot down its opposition to Merck Sharp & Dohme's patent application for an injectable anti-parasite drug for livestock.
The High Court has rejected plumbing company Repipe's application to hear its case centred on the question of patent eligibility for computer-implemented inventions, saying the case was not an appropriate vehicle for special leave.
Apple is “unlikely” to avoid production of the source code for its Touch ID and Face ID technology to an Australian non-practicing entity that has sued the Silicon Valley company for patent infringement, a judge has said.
The Full Federal Court won't give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.
Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.
The ACCC has refused to authorise a patent settlement and license agreement between Bristol-Myers Squibb unit Celgene and two generic drug makers who sued to invalidate the patents for its blockbuster cancer drug Revlimid, saying it could distort competition between generic drug makers.
The Full Court has upheld two judgments that shortened patent term extensions granted to Merck Sharpe & Dohme and Ono Pharmaceuticals, finding the extension regime cannot be construed as achieving a "commercial outcome for a patentee".